Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review.
| Autor: | Domingues G; Internal Medicine - Gastroenterology Department, Medical School, State University of Rio de Janeiro, Rio de Janeiro, Brazil., Chinzon D; Gastroenterology Department, Medical School, University of Sao Paulo, Sao Paulo, Brazil., Moraes-Filho JPP; Gastroenterology Department, Medical School, University of Sao Paulo, Sao Paulo, Brazil., Senra JT; Takeda Pharmaceuticals, Sao Paulo, Brazil., Perrotti M; Takeda Pharmaceuticals, Sao Paulo, Brazil., Zaterka S; Gastroenterology Department, Medical School, University of Sao Paulo, Sao Paulo, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Przeglad gastroenterologiczny [Prz Gastroenterol] 2023; Vol. 18 (1), pp. 47-55. Date of Electronic Publication: 2022 Aug 15. |
| DOI: | 10.5114/pg.2022.116673 |
| Abstrakt: | Introduction: A new therapeutic class, potassium-competitive acid blockers (P-CABs), has emerged in Brazil to promote a superior antisecretory effect addressing the unmet needs related to acid-related disease management. Vonoprazan fumarate showed a good safety profile and was approved by the Brazilian regulatory agency - ANVISA. Aim: This narrative review was conducted to review the general concepts regarding P-CABs, focussing on vonoprazan fumarate. Material and Methods: A literature search was conducted through April-May 2021 using official databases with a combination of MeSH controlled vocabulary and text words. The authors selected articles that described pivotal and novel insights about P-CABs and vonoprazan fumarate. Results: Vonoprazan is a drug of the P-CABs class newly approved for the management of acid-related diseases in Brazil. P-CABs achieve rapid, potent, and prolonged acid suppression (including night-time) and promise to address some unmet clinical needs in GERD. Furthermore, considering the difficulties encountered in attaining effective symptomatic control - particularly at night - using currently available PPIs, this new drug class is promising. Conclusions: This review brings important information about vonoprazan, a new therapeutic option in Brazil, which may be considered as a valuable tool for managing acid-related diseases. Competing Interests: GD and JPPMF have received fees as speakers for Takeda. DC has received fees as an advisory board member for Takeda. JTS and MP are Takeda Pharmaceuticals Brazil full-time employees. Takeda Pharmaceuticals Brazil funded this work. (Copyright © 2023 Termedia.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|